Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease

Cerebrospinal fluid (CSF) and serum biomarkers are critical for clinical decision making in neurological diseases. In cerebral small vessel disease (CSVD), white matter hyperintensities (WMH) are an important neuroimaging biomarker, but more blood-based biomarkers capturing different aspects of CSVD pathology are needed. In 42 sporadic CSVD patients, we prospectively analysed WMH on magnetic resonance imaging (MRI) and the biomarkers neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), chitinase3-like protein 1 (CHI3L1), Tau and Aβ1-42 in CSF and NfL and GFAP in serum. GFAP and CHI3L1 expression was studied in post-mortem brain tissue in additional cases. CSVD cases with higher serum NfL and GFAP levels had a higher modified Rankin Scale (mRS) and NIHSS score and lower CSF Aβ1-42 levels, whereas the CSF NfL and CHI3L1 levels were positively correlated with the WMH load. Moreover, the serum GFAP levels significantly correlated with the neurocognitive functions. Pathological analyses in CSVD revealed a high density of GFAP-immunoreactive fibrillary astrocytic processes in the periventricular white matter and clusters of CHI3L1-immunoreactive astrocytes in the basal ganglia and thalamus. Thus, besides NfL, serum GFAP is a highly promising fluid biomarker of sporadic CSVD, because it does not only correlate with the clinical severity but also correlates with the cognitive function in patients.

[1]  J. Bennett,et al.  Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker , 2021, Annals of neurology.

[2]  F. de Leeuw,et al.  Serum Neurofilament Light Chain Is Associated with Incident Lacunes in Progressive Cerebral Small Vessel Disease , 2020, Journal of stroke.

[3]  A. Brück,et al.  Optical coherence tomography-based assessment of retinal vascular pathology in cerebral small vessel disease , 2020, Neurological Research and Practice.

[4]  Val J Lowe,et al.  Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. , 2020, JAMA neurology.

[5]  H. Braak,et al.  Histological correlates of postmortem ultra-high-resolution single-section MRI in cortical cerebral microinfarcts , 2020, Acta Neuropathologica Communications.

[6]  J. Hong,et al.  Deletion of Chitinase-3-like 1 accelerates stroke development through enhancement of Neuroinflammation by STAT6-dependent M2 microglial inactivation in Chitinase-3-like 1 knockout mice , 2020, Experimental Neurology.

[7]  D. Lulé,et al.  Clinical and neuroimaging disparity between Chinese and German patients with cerebral small vessel disease: a comparative study , 2019, Scientific Reports.

[8]  J. Kira,et al.  Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD , 2019, Neurology.

[9]  R. Kalaria,et al.  Brain‐derived and circulating vesicle profiles indicate neurovascular unit dysfunction in early Alzheimer’s disease , 2019, Brain pathology.

[10]  M. Dichgans,et al.  Small vessel disease: mechanisms and clinical implications , 2019, The Lancet Neurology.

[11]  P. Gunawan,et al.  Glial Fibrillary Acidic Protein Serum Level as a Predictor of Clinical Outcome in Ischemic Stroke , 2019, Open access Macedonian journal of medical sciences.

[12]  K. Blennow,et al.  Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke , 2019, Neuroscience Letters.

[13]  S. Meuth,et al.  Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker? , 2019, Front. Neurol..

[14]  Nick C Fox,et al.  Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.

[15]  T. Tatlisumak,et al.  Astrocyte activation and reactive gliosis—A new target in stroke? , 2019, Neuroscience Letters.

[16]  P. Lewczuk,et al.  Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. , 2019, Journal of Alzheimer's disease : JAD.

[17]  L. Airas,et al.  Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity , 2020, Multiple sclerosis.

[18]  I. Katona,et al.  Endothelial damage, vascular bagging and remodeling of the microvascular bed in human microangiopathy with deep white matter lesions , 2018, Acta Neuropathologica Communications.

[19]  J. Kassubek,et al.  Serum GFAP as a biomarker for disease severity in multiple sclerosis , 2018, Scientific Reports.

[20]  John H. Zhang,et al.  Cerebral Small Vessel Disease , 2018, Cell transplantation.

[21]  Harman S. Suri,et al.  Cerebral Small Vessel Disease: A Review Focusing on Pathophysiology, Biomarkers, and Machine Learning Strategies , 2018, Journal of stroke.

[22]  Ludwig Kappos,et al.  Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.

[23]  F.‐E. Leeuw,et al.  Cerebral small vessel disease: from a focal to a global perspective , 2018, Nature Reviews Neurology.

[24]  F. de Leeuw,et al.  Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden , 2018, Journal of stroke.

[25]  C. Enzinger,et al.  Serum neurofilament light is sensitive to active cerebral small vessel disease , 2017, Neurology.

[26]  Henrik Zetterberg,et al.  Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.

[27]  F. de Leeuw,et al.  A Novel Imaging Marker for Small Vessel Disease Based on Skeletonization of White Matter Tracts and Diffusion Histograms , 2016, Annals of neurology.

[28]  R. Hayes,et al.  Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients , 2016, Scientific Reports.

[29]  A. Valadka,et al.  Biomarkers for acute diagnosis and management of stroke in neurointensive care units , 2016, Brain circulation.

[30]  J. Montaner,et al.  Blood and CSF biomarkers in brain subcortical ischemic vascular disease: Involved pathways and clinical applicability , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  P. Scheltens,et al.  White matter hyperintensities, cognitive impairment and dementia: an update , 2015, Nature Reviews Neurology.

[32]  Joanna M. Wardlaw,et al.  Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden , 2014, Neurology.

[33]  Andreas U. Monsch,et al.  The Extension of the German CERAD Neuropsychological Assessment Battery with Tests Assessing Subcortical, Executive and Frontal Functions Improves Accuracy in Dementia Diagnosis , 2014, Dementia and Geriatric Cognitive Disorders Extra.

[34]  W. Becker,et al.  Do eye movement impairments in patients with small vessel cerebrovascular disease depend on lesion load or on cognitive deficits? A video-oculographic and MRI study , 2014, Journal of Neurology.

[35]  M. Dichgans,et al.  Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging , 2013, The Lancet Neurology.

[36]  A. Postma,et al.  Association between Subcortical Vascular Lesion Location and Cognition: A Voxel-Based and Tract-Based Lesion-Symptom Mapping Study. The SMART-MR Study , 2013, PloS one.

[37]  W. M. van der Flier,et al.  White Matter Lesion Progression in LADIS: Frequency, Clinical Effects, and Sample Size Calculations , 2012, Stroke.

[38]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[39]  W. Brown,et al.  Review: Cerebral microvascular pathology in ageing and neurodegeneration , 2011, Neuropathology and applied neurobiology.

[40]  A. Monsch,et al.  Early detection of Alzheimer’s disease with a total score of the German CERAD , 2010, Journal of the International Neuropsychological Society.

[41]  H. Markus,et al.  The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis , 2010, BMJ : British Medical Journal.

[42]  L. Pantoni.  Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges , 2010, The Lancet Neurology.

[43]  A. Starkey,et al.  In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases , 2010, Journal of Neuroinflammation.

[44]  K. Blennow,et al.  Cerebrospinal fluid biomarkers of white matter lesions – cross‐sectional results from the LADIS study , 2010, European journal of neurology.

[45]  Olivier Rouaud,et al.  Joint effect of white matter lesions and hippocampal volumes on severity of cognitive decline: the 3C-Dijon MRI study. , 2010, Journal of Alzheimer's disease : JAD.

[46]  J. Fleming,et al.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.

[47]  D. Harvey,et al.  Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD , 2006, Neurology.

[48]  W. M. van der Flier,et al.  Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[49]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[50]  O Almkvist,et al.  Visual Rating of Age-Related White Matter Changes on Magnetic Resonance Imaging: Scale Comparison, Interrater Agreement, and Correlations With Quantitative Measurements , 2003, Stroke.

[51]  F. Barkhof,et al.  CT and MRI Rating of White Matter Lesions , 2002, Cerebrovascular Diseases.

[52]  R. Kalaria.  Small Vessel Disease and Alzheimer’s Dementia: Pathological Considerations , 2002, Cerebrovascular Diseases.

[53]  K. Blennow,et al.  Neurofilament protein in cerebrospinal fluid: A marker of white matter changes , 2001, Journal of neuroscience research.

[54]  M. Breteler,et al.  Vascular risk factors for Alzheimer’s disease: An epidemiologic perspective , 2000, Neurobiology of Aging.

[55]  F. Fazekas,et al.  Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment , 1995, Journal of the Neurological Sciences.

[56]  J. Marler,et al.  Measurements of acute cerebral infarction: a clinical examination scale. , 1989, Stroke.

[57]  R. Bloch,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.